pd 153035 has been researched along with raltitrexed in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gangjee, A; Ihnat, M; Kisliuk, RL; Raghavan, S; Shenoy, S; Zaware, N | 1 |
| Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Kisliuk, RL; Thorpe, JE; Zhao, Y | 1 |
2 other study(ies) available for pd 153035 and raltitrexed
| Article | Year |
|---|---|
Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Indoles; Male; Mice; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Structure-Activity Relationship; Sulfhydryl Compounds; Thymidylate Synthase; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Indenes; Melanoma, Experimental; Mice; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2012 |